|
1
|
Ferlay J, Shin HR, Bray F, et al:
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int
J Cancer. 127:2893–2917. 2010.
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012.
|
|
3
|
European Association For The Study Of The
Liver1; European Organisation For Research And Treatment Of Cancer.
EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.
|
|
4
|
Ranieri G, Gadaleta-Caldarola G, Goffredo
V, et al: Sorafenib (BAY 43-9006) in hepatocellular carcinoma
patients: from discovery to clinical development. Curr Med Chem.
19:938–944. 2012.
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008.
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, et al:
Efficacy and safety of sorafenib in patients in the Asia-Pacific
region with advanced hepatocellular carcinoma: a phase III
randomised, double-blind, placebo-controlled trial. Lancet Oncol.
10:25–34. 2009.
|
|
7
|
Fiorentini G and Szasz A: Hyperthermia
today: electric energy, a new opportunity in cancer treatment. J
Cancer Res Ther. 2:41–46. 2006.
|
|
8
|
Roca C, Primo L, Valdembri D, et al:
Hyperthermia inhibits angiogenesis by a plasminogen activator
inhibitor 1-dependent mechanism. Cancer Res. 63:1500–1507.
2003.
|
|
9
|
Hildebrandt B, Wust P, Ahlers O, et al:
The cellular and molecular basis of hyperthermia. Crit Rev Oncol
Hematol. 43:33–56. 2002.
|
|
10
|
van der Zee J: Heating the patient: a
promising approach? Ann Oncol. 13:1173–1184. 2002.
|
|
11
|
Horsman MR: Angiogenesis and vascular
targeting: relevance for hyperthermia. Int J Hyperthermia.
24:57–65. 2008.
|
|
12
|
Ranieri G, Catino A, Mattioli V, et al:
Targeting tumour vascularization from bench to bedside: Some
suggestions for combination with hyperthermia. Cancer
Microenvironment and Therapeutic Implications. Baronzio G,
Fiorentini G and Cogle CR: 1st edition. Springer Science + Business
Media B.V; Dordrecht: pp. 203–219. 2009
|
|
13
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, et al: New guidelines to evaluate the response to
treatment in solid tumors. European Organization for Research and
Treatment of Cancer, National Cancer Institute of the United
States, National Cancer Institute of Canada. J Natl Cancer Inst.
92:205–216. 2000.
|
|
14
|
Bruggmoser G, Bauchowitz S, Canters R,
Crezee H, et al; ESHO Technical Committee in the Interdisciplinary
Working Group Hyperthermia (IAH) in the German Cancer Society.
Quality assurance for clinical studies in regional deep
hyperthermia. Strahlenther Onkol. 187:605–610. 2011.
|
|
15
|
NCI. Common Terminology Criteria for
Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/forms/CTCAEv3.pdf.
Accessed January 8, 2009
|
|
16
|
Lacouture ME, Wu S, Robert C, Atkins MB,
et al: Evolving strategies for the management of hand-foot skin
reaction associated with the multitargeted kinase inhibitors
sorafenib and sunitinib. Oncologist. 13:1001–1011. 2008.
|
|
17
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
|
|
18
|
Cancer Therapy Evaluation Program. Common
Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Accessed August 9, 2006
|
|
19
|
Yuan GJ, Li QW, Shan SL, et al:
Hyperthermia inhibits hypoxia-induced epithelial-mesenchymal
transition in HepG2 hepatocellular carcinoma cells. World J
Gastroenterol. 18:4781–4786. 2012.
|
|
20
|
Xu XM, Yuan GJ, Li QW, Shan SL and Jiang
S: Hyperthermia inhibits transforming growth factor beta-induced
epithelial-mesenchymal transition (EMT) in HepG2 hepatocellular
carcinoma cells. Hepatogastroenterology. 59:2059–2063. 2012.
|
|
21
|
Mayrhauser U, Stiegler P, Stadlbauer V,
Koestenbauer S, et al: Effect of hyperthermia on liver cell lines:
important findings for thermal therapy in hepatocellular carcinoma.
Anticancer Res. 31:1583–1588. 2011.
|
|
22
|
Ferrari VD, De Ponti S, Valcamonico F, et
al: Deep electro-hyperthermia (EHY) with or without thermo-active
agents in patients with advanced hepatic cell carcinoma: Phase II
study. J Clin Oncol. 25(S): Abstract 151682007.
|
|
23
|
Krawczyka PM, Eppinkb B, Essers J, Stap J,
et al: Mild hyperthermia inhibits homologous recombination, induces
BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose)
polymerase-1 inhibition. Proc Natl Acad Sci USA. 24:9851–9856.
2011.
|
|
24
|
Gadaleta CD, Catino A, Ranieri G, Fazio V,
et al: Single-step therapy - feasibility and safety of simultaneous
transarterial. chemoembolization and radiofrequency ablation for
hepatic malignancies. In vivo. 23:813–820. 2009.
|
